Adipogenic action of vanadium: A new dimension in treating diabetes

Ruchi Shukla; Ramesh R. Bhonde

doi:10.1007/s10534-007-9109-4

Adipogenic action of vanadium: A new dimension in treating diabetes

Ruchi Shukla, Ramesh R. Bhonde

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Vanadium is a well known anti-diabetic agent which mimics most of the actions of insulin on mature adipocytes. We report here the effect of vanadium on proliferation and differentiation of 3T3-L1 preadipocytes. Like insulin, vanadium treatment leads to increased proliferation as evidenced by H ³thymidine uptake studies and differentiation of 3T3-L1 cells into adipocytes as evidenced by oil-red-O staining. Adipogenic potential of vanadium can be attributed to CREB activation, as documented by phospho-CREB antibody staining. This adipogenic potential is of significance in an in vivo scenario as the new adipocytes are likely to be insulin sensitive as against resistant existing mature adipocytes and thus indirectly may help in reduction of insulin resistance. Till today decrease in insulin resistance by vanadium treatment has been mainly attributed to its potential to inhibit PTP-1B, however the present study opens a new dimension in vanadium treatment for diabetes due to its novel role in adipogenesis.

Original language	English
Pages (from-to)	205-210
Number of pages	6
Journal	BioMetals
Volume	21
Issue number	2
DOIs	https://doi.org/10.1007/s10534-007-9109-4
Publication status	Published - Apr 2008
Externally published	Yes

Keywords

3T3-L1 cells
Adipogenesis
CREB activation
Vanadium

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10534-007-9109-4

Cite this

@article{b222cba10f404f0ba21b76227c2b747e,

title = "Adipogenic action of vanadium: A new dimension in treating diabetes",

abstract = "Vanadium is a well known anti-diabetic agent which mimics most of the actions of insulin on mature adipocytes. We report here the effect of vanadium on proliferation and differentiation of 3T3-L1 preadipocytes. Like insulin, vanadium treatment leads to increased proliferation as evidenced by H 3thymidine uptake studies and differentiation of 3T3-L1 cells into adipocytes as evidenced by oil-red-O staining. Adipogenic potential of vanadium can be attributed to CREB activation, as documented by phospho-CREB antibody staining. This adipogenic potential is of significance in an in vivo scenario as the new adipocytes are likely to be insulin sensitive as against resistant existing mature adipocytes and thus indirectly may help in reduction of insulin resistance. Till today decrease in insulin resistance by vanadium treatment has been mainly attributed to its potential to inhibit PTP-1B, however the present study opens a new dimension in vanadium treatment for diabetes due to its novel role in adipogenesis.",

keywords = "3T3-L1 cells, Adipogenesis, CREB activation, Vanadium",

author = "Ruchi Shukla and Bhonde, {Ramesh R.}",

note = "Funding Information: Acknowledgement Authors wish to thank Director, NCCS for providing all the experimental facilities and Council for scientific and industrial research (CSIR), India for research fellowship to RS. Also the authors thank Dr Subhash Padhye for providing VOSO4.",

year = "2008",

month = apr,

doi = "10.1007/s10534-007-9109-4",

language = "English",

volume = "21",

pages = "205--210",

journal = "BioMetals",

issn = "0966-0844",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Adipogenic action of vanadium

T2 - A new dimension in treating diabetes

AU - Shukla, Ruchi

AU - Bhonde, Ramesh R.

N1 - Funding Information: Acknowledgement Authors wish to thank Director, NCCS for providing all the experimental facilities and Council for scientific and industrial research (CSIR), India for research fellowship to RS. Also the authors thank Dr Subhash Padhye for providing VOSO4.

PY - 2008/4

Y1 - 2008/4

N2 - Vanadium is a well known anti-diabetic agent which mimics most of the actions of insulin on mature adipocytes. We report here the effect of vanadium on proliferation and differentiation of 3T3-L1 preadipocytes. Like insulin, vanadium treatment leads to increased proliferation as evidenced by H 3thymidine uptake studies and differentiation of 3T3-L1 cells into adipocytes as evidenced by oil-red-O staining. Adipogenic potential of vanadium can be attributed to CREB activation, as documented by phospho-CREB antibody staining. This adipogenic potential is of significance in an in vivo scenario as the new adipocytes are likely to be insulin sensitive as against resistant existing mature adipocytes and thus indirectly may help in reduction of insulin resistance. Till today decrease in insulin resistance by vanadium treatment has been mainly attributed to its potential to inhibit PTP-1B, however the present study opens a new dimension in vanadium treatment for diabetes due to its novel role in adipogenesis.

AB - Vanadium is a well known anti-diabetic agent which mimics most of the actions of insulin on mature adipocytes. We report here the effect of vanadium on proliferation and differentiation of 3T3-L1 preadipocytes. Like insulin, vanadium treatment leads to increased proliferation as evidenced by H 3thymidine uptake studies and differentiation of 3T3-L1 cells into adipocytes as evidenced by oil-red-O staining. Adipogenic potential of vanadium can be attributed to CREB activation, as documented by phospho-CREB antibody staining. This adipogenic potential is of significance in an in vivo scenario as the new adipocytes are likely to be insulin sensitive as against resistant existing mature adipocytes and thus indirectly may help in reduction of insulin resistance. Till today decrease in insulin resistance by vanadium treatment has been mainly attributed to its potential to inhibit PTP-1B, however the present study opens a new dimension in vanadium treatment for diabetes due to its novel role in adipogenesis.

KW - 3T3-L1 cells

KW - Adipogenesis

KW - CREB activation

KW - Vanadium

UR - http://www.scopus.com/inward/record.url?scp=41049083130&partnerID=8YFLogxK

U2 - 10.1007/s10534-007-9109-4

DO - 10.1007/s10534-007-9109-4

M3 - Article

C2 - 17671828

AN - SCOPUS:41049083130

SN - 0966-0844

VL - 21

SP - 205

EP - 210

JO - BioMetals

JF - BioMetals

IS - 2

ER -

Adipogenic action of vanadium: A new dimension in treating diabetes

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this